κWhen microglia wind up with a belly full of lipid droplets, it’s a sign that the cells are rallying, perhaps in vain, to a neurodegenerative threat. But according to a study published July 10 in Cell ...

Machine learning software sharpens the diagnostic utility of FDG PET scans. StateViewer told apart nine neurodegenerative diseases with 93 percent accuracy. Using the program made radiologists three ...

Is Alzheimer’s disease different in people with Down’s? Two recent proteomics studies say yes. In the July 1 Nature Communications, scientists led by Erik Johnson at Emory University School of ...

Every participant in the Dutch 100-Plus study is, by definition, exceptional. Just to qualify for enrollment, they must have remained cognitively healthy even after logging 100 laps around the sun.

Nowadays, in the hunt for biomarkers of Alzheimer’s and related diseases, blood is where it’s at. Blood draws are cheaper and easier than other options, and clinical trial participants prefer them, ...

Massage might help your brain flow regain its mojo. On June 4 in Nature, researchers led by Gou Young Koh at the Institute for Basic Science in Daejeon, South Korea, mapped the labyrinth of lymphatics ...

On April 15, two years after Eisai requested a marketing license for lecanemab in Europe, the European Commission has greenlit its use. The biologic’s long path included an initial rejection from the ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

A new multiplex diagnostic method appears poised to resculpt the biomarker landscape. NULISA, aka NUcleic acid Linked Immunosorbent Assay, can detect Aβ peptides, p-tau isoforms, and other potential ...